Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.060 -0.530 (-5.53%)
Streaming Delayed Price Updated: 12:48 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Prothena Corp Earnings Preview ↗
 
Via Benzinga
News headline image
Another Sucess In Alzheimer’s Disease ↗
Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments? 
Via Talk Markets
News headline image
Prothena to Report First Quarter 2023 Financial Results on May 4
From Prothena Corporation plc
Via Business Wire
News headline image
Where Prothena Corp Stands With Analysts ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Prothena Corp ↗
 
Via Benzinga
News headline image
Earnings Outlook For Prothena Corp ↗
 
Via Benzinga
News headline image
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate ↗
 
Via Benzinga
News headline image
Prothena to Participate in 2023 Bank of America Healthcare Conference
From Prothena Corporation plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 ↗
 
Via Benzinga
News headline image
Analyst Expectations for Prothena Corp's Future ↗
 
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial
From Walgreens
Via Business Wire
News headline image
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Participate in Stifel 2023 Virtual CNS Days
From Prothena Corporation plc
Via Business Wire
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... 
Via FinancialNewsMedia
News headline image
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Earnings Scheduled For February 23, 2023 ↗
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Prothena Corporation plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗
 
Via Benzinga
News headline image
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish ↗
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. 
Via Talk Markets
News headline image
How To Weather These Choppy Markets ↗
Until we get an absolute bottom in the markets, the best way to avoid experiencing a devastating permanent loss of capital is to keep away from stocks with deteriorating fundamentals and heavy insider... 
Via Talk Markets
News headline image
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease ↗
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... 
Via Talk Markets
News headline image
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
From Prothena Corporation plc
Via Business Wire
News headline image
Why Prothena Shares Are Trading Lower ↗
Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by 6.53% to $59.10 during Wednesday morning. The company announced that it has commenced an underwritten public offering of 3,000,000 of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.